Research Breakthrough for Juvenile Rheumatoid Arthritis
Humira (adalimumab) is providing a profound benefit for children with juvenile rheumatoid arthritis and is well-tolerated, says Cincinatti researchers. The results of clinical trials are so significant that “we can now make the disease almost a non-issue" for children.
Knowledge for Health – Cochrane Symposium
Ottawa, February 11 – 12
Registration for the 5th CANADIAN COCHRANE SYMPOSIUM is now open! Consumers are encouraged to attend. Financial stipends are available to consumers (non-staff) belonging to health associations. Deadline for early bird registration is January 12, 2007.
Information from IMHA about Pain and Pain Research
The Institute of Musculoskeletal Health and Arthritis (IMHA) of the Canadian Institutes of Health Research (CIHR), is committed, through research, to sustaining health and enhancing the quality of life by eradicating the pain, suffering and disability caused by arthritis, musculoskeletal, oral and skin conditions. Recognizing that patients/consumers make an important contribution towards creating a research agenda that addresses the most pressing health issues of the day, IMHA has created a Knowledge Exchange Task Force (KETF) committed to building communication pathways linking researchers and other stakeholders.
For more information about the KETF and on chronic pain and its management, please visit http://www.cihr-irsc.gc.ca/e/32389.html.